Revvity, Inc. (NYSE:RVTY) Shares Purchased by Cetera Investment Advisers

Cetera Investment Advisers lifted its holdings in shares of Revvity, Inc. (NYSE:RVTY) by 17.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,786 shares of the company’s stock after purchasing an additional 848 shares during the quarter. Cetera Investment Advisers’ holdings in Revvity were worth $646,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Assetmark Inc. increased its position in shares of Revvity by 3,700.0% during the fourth quarter. Assetmark Inc. now owns 266 shares of the company’s stock worth $30,000 after acquiring an additional 259 shares during the period. Optiver Holding B.V. acquired a new stake in Revvity during the 4th quarter worth $33,000. Quarry LP raised its stake in Revvity by 45.7% during the 4th quarter. Quarry LP now owns 303 shares of the company’s stock valued at $34,000 after acquiring an additional 95 shares during the last quarter. Millstone Evans Group LLC acquired a new position in Revvity in the 4th quarter valued at $38,000. Finally, EverSource Wealth Advisors LLC increased its position in Revvity by 33.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company’s stock worth $58,000 after purchasing an additional 131 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

Shares of RVTY opened at $89.47 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03. Revvity, Inc. has a 12 month low of $88.01 and a 12 month high of $129.50. The stock has a fifty day moving average price of $96.71 and a 200 day moving average price of $109.11. The company has a market cap of $10.55 billion, a P/E ratio of 40.48, a PEG ratio of 3.82 and a beta of 1.02.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Monday, April 28th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.05. The company had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the company earned $0.98 earnings per share. On average, research analysts forecast that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date is Friday, July 18th. Revvity’s payout ratio is 11.91%.

Analysts Set New Price Targets

A number of research analysts have issued reports on RVTY shares. Barclays dropped their target price on shares of Revvity from $140.00 to $110.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Raymond James reaffirmed an “outperform” rating and set a $120.00 price target (down previously from $145.00) on shares of Revvity in a research report on Tuesday, April 29th. The Goldman Sachs Group cut their price target on shares of Revvity from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Wells Fargo & Company dropped their target price on Revvity from $130.00 to $102.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Finally, Robert W. Baird cut their price target on Revvity from $127.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, April 29th. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $125.64.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.